Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity

British Journal of Clinical Pharmacology

Volumn 58, Issue 2, 2004, Pages 190-200

  Ernstgård, Lena ^a   Warholm, Margareta ^a   Johanson, Gunnar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

6 hydroxychlorzoxazone; Body build; Chlorzoxazone; CYP2E1; Dose dependence; Ethanol; Human; Metabolic ratio

Indexed keywords

6 HYDROXYCHLORZOXAZONE; ALCOHOL; ARYLAMINE ACETYLTRANSFERASE; CHLORZOXAZONE; CYTOCHROME P450 2E1; DRUG METABOLITE; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE; UNCLASSIFIED DRUG;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOOD SAMPLING; BODY BUILD; BODY FAT; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL;

ADULT; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; DNA; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; POLYMORPHISM, GENETIC;

EID: 3843092925     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02132.x     Document Type: Article

References (43)

1. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1-21.
2. Raucy JL. Risk assessment:. toxicity from chemical exposure resulting from enhanced expression of CYP2E1. Toxicology 1995; 105: 217-24.
3. Kim H, Wang RS, Elovaara E, et al. Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica 1997; 27: 657-65.
4. Lieber CS. Cytochrome P-4502E1: Its physiological and pathological role. Physiol Rev 1997; 77: 517-44.
5. Yoo JS, Guengerich FP, Yang CS. Metabolism of N-nitrosodialkylamines by human liver microsomes. Cancer Res 1988; 48: 1499-504.
6. Hunt CM, Strater S, Stave GM. Effect of normal aging on the activity of human hepatic cytochrome P450IIE1. Biochem Pharmacol 1990; 40: 1666-9.
7. Kim RB, O'Shea D. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 1995; 57: 645-55.
8. Girre C, Lucas D, Hispard E, et al. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994; 47: 1503-8.
9. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone. a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994; 56: 359-67.
10. Dilger K, Metzler J, Bode JC, Klotz U. CYP2E1 activity in patients with alcoholic liver disease. J Hepatol 1997; 27: 1009-14.
11. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. Clin Pharmacol Ther 1993; 53: 643-50.
12. Carriere V, Berthou F, Baird S, et al. Human cytochrome P450 2E1 (CYP2E1): From genotype to phenotype. Pharmacogenetics 1996; 6: 203-11.
13. Haufroid V, Buchet JP, Gardinal S, Lison D. Cytochrome P4502E1 phenotyping by the measurement of the chlorzoxazone metabolic ratio: assessment of its usefulness in workers exposed to styrene. Int Arch Occup Environ Health 2002; 75: 453-8.
14. Le Marchand L, Wilkinson GR, Wilkens LR. Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol Biomarkers Prev 1999; 8: 495-500.
15. Lucas D, Ferrara R, Gonzalez E, et al. Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. Pharmacogenetics 1999; 9: 377-88.
16. Twele R, Spiteller G. [Identification of chlorzoxazone metabolites in human urine (author's transl) ]. Arzneimittelforschung 1982; 32: 759-63.
17. Droz PO, Wu MM, Cumberland WG, Berode M. Variability in biological monitoring of solvent exposure. I. Development of a population physiological model. Br J Ind Med 1989; 46: 447-60.
18. Stiff DD, Frye RF, Branch RA. Sensitive high-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in plasma. J Chromatogr 1993; 613: 127-31.
19. Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from nucleated cells. Nucl Acids Res 1988; 16: 1215.
20. Persson I, Johansson I, Bergling H, et al. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. FEBS Lett 1993; 319: 207-11.
21. Hu Y, Hakkola J, Oscarson M, Ingelman-Sundberg M. Structural and functional characterization of the 5′-flanking region of the rat and human cytochrome P450 2E1 genes: Identification of a polymorphic repeat in the human gene. Biochem Biophys Res Commun 1999; 263: 286-93.
22. Fritsche E, Pittman GS. Bell DA. Localization, sequence analysis, and ethnic distribution of a 96-bp insertion in the promoter of the human CYP2E1 gene. Mut Res Genom 2000; 432: 1-5.
23. Fairbrother KS, Grove J, de Waziers I, et al. Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 1998; 8: 543-52.
24. Haufroid V, Clippe A, Knoops B, Bernard A, Lison D. Genotyping in urine: an interesting tool for epidemiological studies. Clin Chem 1998; 44: 2210-11.
25. Brockmöller J, Gross D, Kerb R, Drakoulis N, Roots I. Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class Mu gene detected by polymerase chain reaction. Biochem Pharmacol 1992; 43: 647-50.
26. Tuominen R, Baranczewski P, Warholm M, et al. Susceptibility factors and DNA adducts in peripheral blood mononuclear cells of aluminium smelter workers exposed to polycyclic aromatic hydrocarbons. Arch Toxicol 2002; 76: 178-86.
27. Bachmann K, Sarver JG. Chlorzoxazone as a single sample probe of hepatic CYP2E1 activity in humans. Pharmacology 1996; 52: 169-77.
28. McCarver DG, Byun R, Hines RN, Hichme M, Wegenek W. A Genetic polymorphism in the regulatory sequences of human CYP2E1 - Association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol 1998; 152: 276-81.
29. Frye RF, Adedoyin A, Mauro K, Matzke GR, Branch RA. Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. J Clin Pharmacol 1998; 38: 82-9.
30. De Vries JD, Salphati L, Horie S, Becker CE, Hoener B-A. Variability in the disposition of chlorzoxazone. Biopharm Drug Disposit 1994; 15: 587-97.
31. Desiraju RK, Renzi NLJ, Nayak RK, Kung-Tat N. Pharmacokinetics of chlorzoxazone in humans. J Pharm Sci 1983; 72: 991-4.
32. Ferrara A, Barrett-Connor E, Wingård DL, Edelstein SL. Sex differences in insulin levels in older adults and the effect of body size, estrogen replacement therapy, and glucose tolerance status. The Rancho Bernardo Study, 1984-87. Diabetes Care 1995; 18: 220-5.
33. Ernstgård L, Sjögren B, Warholm M, Johanson G. Sex differences in the toxicokinetics of inhaled solvent vapors in humans 1. m-Xylene. Toxicol Appl Pharmacol 2003; 193: 147-57.
34. Ernstgård L, Sjögren B, Warholm M, Johanson G. Sex differences in the toxicokinetics of inhaled solvent vapors in humans 2. 2-Propanol. Toxicol Appl Pharmacol 2003; 193: 158-67.
35. Ernstgård L, Gullstrand E, Johanson G, Löf A. Toxicokinetic interactions between orally ingested chlorzoxazone and inhaled acetone or toluene in male volunteers. Toxicol Sci 1999; 48: 189-96.
36. Lucas D, Menez C, Girre C, et al. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics 1995; 5: 298-304.
37. Haufroid V, Buchet JP, Gardinal S, et al. Importance of genetic polymorphisms of drug-metabolizing enzymes for the interpretation of biomarkers of exposure to styrene. Biomarkers 2001; 6: 236-49.
38. Nakajima M, Yoshida R, Shimada N, Yamazaki H, Yokoi T. Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. Drug Metab Dispos 2001; 29: 1110-13.
39. Zhao B, Seow A, Lee EJ, et al. Dietary isothiocyanates, glutathione S-transferase-M1-T1 polymorphisms and lung cancer risk among Chinese women in Singapore. Cancer Epidemiol Biomarkers Prev 2001; 10: 1063-7.
40. Lucas D, Menez C, DuPont I, et al. Clinical interest of the in vivo measurement of CYP2E1 in alcoholic liver diseases. Alcohol Clin Exp Res 1998; 22: 745-6.
41. Benowitz NL, Peng M, Jacob P. 3rd. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharmacol Ther 2003; 74: 468-74.
42. Plee-Gautier E, Foresto F, Ferrara R, et al. Genetic repeat polymorphism in the regulating region of CYP2E1: frequency and relationship with enzymatic activity in alcoholics. Alcohol Clin Exp Res 2001; 25: 800-4.
43. Oneta CM, Lieber CS, Li J, et al. Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase. J Hepatol 2002; 36: 47-52.